NDA 021693 · Shionogi INC
Rybix Odt
Tramadol Hydrochloride · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 13, 2010 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
May 5, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
477
87 Phase 3, 25 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- RYBIX ODT · TRAMADOL HYDROCHLORIDE 50MG · TABLET, ORALLY DISINTEGRATING, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Tramadol" as an intervention, any sponsor and status, largest first.
- Comparison of Pain Therapeutic Effects After Benign MastectomyPivotal-lookingCompleted
Nanjing Medical UniversityAcademic, hospital or other
NCT00519246 · 2,000 participants · Start Feb 2007 · Primary completion Dec 2007
Drug: Saline; Opioid and 5 more · For: Pain, Postoperative; Mastectomy
Sites: Nanjing, China
- A Phase 3 Study of Tanezumab for Chronic Low Back PainPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02528253 · 1,832 participants · Start Aug 18, 2015 · Primary completion Oct 17, 2017
Drug: Placebo to Week 16; tanezumab 5mg SC; Placebo to Week 16, tanezumab 10 mg SC and 3 more · For: Low Back Pain
Sites: Birmingham, Alabama; Mobile, Alabama; Saraland, Alabama · 262 sites in all
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Paracetamol-Tramadol and Paracetamol-caffeine Versus Placebo in the Emergency Discharge Treatment of Renal ColicPivotal-lookingStatus unknown
University of MonastirAcademic, hospital or other
NCT06345716 · 1,500 participants (planned) · Start Apr 10, 2024 · Primary completion Mar 15, 2025
Drug: paracétamol tramadol; Paracétamol cafeine and 1 more · For: Renal Colic
Sites: Monastir, Tunisia
- Effect of Early Pain Management at Triage on Opioid ConsumptionPivotal-lookingCompleted
University of MonastirAcademic, hospital or other
NCT03243006 · 1,500 participants · Start Jan 1, 2016 · Primary completion Sep 30, 2016
Drug: Paracetamol; Tramadol/Paracetamol combination and 1 more · For: Acute Pain
- Effect of Tramadol in Prevention of Postpartum DepressionPivotal-lookingCompleted
Xinqiao Hospital of ChongqingAcademic, hospital or other
NCT03309163 · 1,230 participants · Start Oct 9, 2017 · Primary completion Jun 13, 2019
Drug: Tramadol; Hydromorphone and 1 more · For: Caesarean Section
Sites: Chongqing, China
- Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar ExtractionPivotal-lookingCompleted
Grünenthal GmbHIndustry
NCT03714672 · 1,151 participants · Start Aug 26, 2017 · Primary completion Mar 9, 2018
Drug: Tramadol/Diclofenac 50/50; Tramadol/Diclofenac 25/25 and 2 more · For: Acute Pain
Sites: Zapopan, Mexico; Monterrey, Mexico; Aguascalientes, Mexico · 8 sites in all
- Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.Pivotal-lookingCompleted
Mundipharma Research GmbH & Co KGIndustry
NCT03062644 · 1,138 participants · Start Apr 5, 2017 · Primary completion Jun 29, 2018
Drug: MR308; MR308 and 2 more · For: Acute Pain
Sites: Minsk, Belarus; Sofia, Bulgaria; London, Canada · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tramadol versus placebo for chronic pain: a systematic review with meta-analysis and trial sequential analysis.
Barakji JA, Maagaard M, Petersen JJ, et al. · BMJ Evid Based Med 2026 · Systematic Review, Meta-Analysis
- Tramadol (with or without acetaminophen) efficacy and harm: Systematic review and meta-analysis.
Otte JA, Chu G, Heran B, et al. · Can Fam Physician 2025 · Systematic Review, Meta-Analysis
- A systematic review and meta-analysis of randomized controlled trials of "on-demand" use of tramadol vs "on-demand" use of paroxetine in the management of patients with premature ejaculation.
Tan H, Zhou Z, Cui Y, et al. · Int J Clin Pract 2021 · Meta-Analysis, Systematic Review
- Efficacy of tramadol for postoperative pain management in dogs: systematic review and meta-analysis.
Donati PA, Tarragona L, Franco JVA, et al. · Vet Anaesth Analg 2021 · Meta-Analysis, Systematic Review
- Tramadol and the occurrence of seizures: a systematic review and meta-analysis.
Nakhaee S, Amirabadizadeh A, Brent J, et al. · Crit Rev Toxicol 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Tramadol for Knee or Hip Osteoarthritis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Zhang X, Li X, Xiong Y, et al. · Arthritis Care Res (Hoboken) 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Shionogi INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.